References
- Pavan-Langston D. Ocular viral infections. Med Clin North Am. 1983;67(5):973–90. doi:https://doi.org/10.1016/S0025-7125(16)31162-2.
- Gokhale NS. Medical management approach to infectious keratitis. Indian J Ophthalmol. 2008;56(3):215. doi:https://doi.org/10.4103/0301-4738.40360.
- Kaye S, Choudhary A. Herpes simplex keratitis. Prog Retin Eye Res. 2006;25(4):355–80. doi:https://doi.org/10.1016/j.preteyeres.2006.05.001.
- Elion GB. The biochemistry and mechanism of action of acyclovir. J Antimicrob Chemother. 1983;12(suppl_B):9–17. doi:https://doi.org/10.1093/jac/12.suppl_B.9.
- Elion GB. Acyclovir: discovery, mechanism of action, and selectivity. J Med Virol. 1993;41:2–6. doi:https://doi.org/10.1002/jmv.1890410503.
- Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother. 2011;55(2):459–72. doi:https://doi.org/10.1128/AAC.00615-10.
- Tsatsos M, MacGregor C, Athanasiadis I, Moschos MM, Hossain P, Anderson D. Herpes simplex virus keratitis: an update of the pathogenesis and current treatment with oral and topical antiviral agents. Clin Exp Ophthalmol. 2016 Dec;44(9):824–37. doi:https://doi.org/10.1111/ceo.12785.
- Smith JP, Weller S, Johnson B, Nicotera J, Luther JM, Haas DW. Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. Antimicrob Agents Chemother. 2010;54(3):1146–51. doi:https://doi.org/10.1128/AAC.00729-09.
- Ghera BB, Perret F, Chevalier Y, Parrot-Lopez H. Novel nanoparticles made from amphiphilic perfluoroalkyl α-cyclodextrin derivatives: preparation, characterization and application to the transport of acyclovir. Int J Pharm. 2009;375(1–2):155–62. doi:https://doi.org/10.1016/j.ijpharm.2009.04.004.
- Araújo J, Gonzalez E, Egea MA, Garcia ML, Souto EB. Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomed-Nanothechnol. 2009;5(4):394–401. doi:https://doi.org/10.1016/j.nano.2009.02.003.
- Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12(3):348–60. doi:https://doi.org/10.1208/s12248-010-9183-3.
- Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008;13(3–4):144–51. doi:https://doi.org/10.1016/j.drudis.2007.10.021.
- Gutiérrez JM, González C, Maestro A, Solè IM, Pey CM, Nano-emulsions: NJ. New applications and optimization of their preparation. Curr Opin Colloid Interface Sci. 2008;13(4):245–51. doi:https://doi.org/10.1016/j.cocis.2008.01.005.
- Solans C, Izquierdo P, Nolla J, Azemar N, Garcia-Celma MJ. Nano-emulsions. Curr Opin Colloid Interface Sci. 2005;10(3–4):102–10. doi:https://doi.org/10.1016/j.cocis.2005.06.004.
- Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today. 2011;16(7–8):354–60. doi:https://doi.org/10.1016/j.drudis.2010.02.009.
- Wang L, Mutch KJ, Eastoe J, Heenan RK, Dong J. Nanoemulsions prepared by a two-step low-energy process. Langmuir. 2008;24(12):6092–99. doi:https://doi.org/10.1021/la800624z.
- Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res. 2002;21(1):15–34. doi:https://doi.org/10.1016/S1350-9462(01)00017-9.
- Ammar HO, Salama HA, Ghorab M, Mahmoud AA. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech. 2009;10(3):808–19. doi:https://doi.org/10.1208/s12249-009-9268-4.
- Shafiq S, Shakeel F. Stability and self-nanoemulsification efficiency of ramipril nanoemulsion containing labrasol and plurol oleique. Clin Res Regul Aff. 2010;27(1):7–12. doi:https://doi.org/10.3109/10601330903571691.
- Butani D, Yewale C, Misra A. Amphotericin B topical microemulsion: formulation, characterization and evaluation. Colloids Surf B. 2014;116:351–58. doi:https://doi.org/10.1016/j.colsurfb.2014.01.014.
- Alany RG, Rades T, Nicoll J, Tucker IG, Davies NM. W/O microemulsions for ocular delivery: evaluation of ocular irritation and precorneal retention. J Control Release. 2006;111(1–2):145–52. doi:https://doi.org/10.1016/j.jconrel.2005.11.020.
- Morsi N, Ibrahim M, Refai H, El Sorogy H. Nanoemulsion-based electrolyte triggered in situ gel for ocular delivery of acetazolamide. Eur J Pharm Sci. 2017;104:302–14. doi:https://doi.org/10.1016/j.ejps.2017.04.013.
- Azeem A, Rizwan M, Ahmad FJ, Iqbal Z, Khar RK, Aqil M, Talegaonkar S. Nanoemulsion components screening and selection: a technical note. Aaps Pharmscitech. 2009;10(1):69–76. doi:https://doi.org/10.1208/s12249-008-9178-x.
- Singh M, Bharadwaj S, Lee KE, Kang SG. Therapeutic nanoemulsions in ophthalmic drug administration: concept in formulations and characterization techniques for ocular drug delivery. J Control Release. 2020;328:895–916. doi:https://doi.org/10.1016/j.jconrel.2020.10.025.
- Kale SN, Deore SL. Emulsion micro emulsion and nano emulsion: a review. Sys Rev Pharm. 2017;8:39.
- Akhter S, Anwar M, Siddiqui MA, Ahmad I, Ahmad J, Ahmad MZ, Bhatnagar A, Ahmad FJ. Improving the topical ocular pharmacokinetics of an immunosuppressant agent with mucoadhesive nanoemulsions: formulation development, in-vitro and in-vivo studies. Colloids Surf B. 2016;148:19–29. doi:https://doi.org/10.1016/j.colsurfb.2016.08.048.
- Soliman OA, Mohamed EA, Khatera NA. Enhanced ocular bioavailability of fluconazole from niosomal gels and microemulsions: formulation, optimization, and in vitro–in vivo evaluation. Pharm Dev Technol. 2019;24(1):48–62. doi:https://doi.org/10.1080/10837450.2017.1413658.
- Radomska-Soukharev AN, Wojciechowska JO. Microemulsions as potential ocular drug delivery systems: phase diagrams and physical properties depending on ingredients. Acta Pol Pharm. 2005;62:465–71.
- Shah J, Nair AB, Jacob S, Patel RK, Shah H, Shehata TM, Morsy MA. Nanoemulsion based vehicle for effective ocular delivery of moxifloxacin using experimental design and pharmacokinetic study in rabbits. Pharmaceutics. 2019;11(5):230. doi:https://doi.org/10.3390/pharmaceutics11050230.
- Van Ooteghem MM. Formulation of ophthalmic solutions and suspensions. Problems and advantages. In: Edman P, editor. Biopharmaceutics of ocular delivery. Boca Raton (FL): CRS Press; 1993. p. 27–42.
- United State Pharmacopeia. Ophthalmic products-quality tests, in USP39-NF34; 2016. pp. 589–95.
- Patel N, Nakrani H, Raval M, Sheth N. Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability. Drug Deliv. 2016;23(9):3712–23. doi:https://doi.org/10.1080/10717544.2016.1223225.
- Kouchak M, Mahmoodzadeh M, Farrahi F. Designing of a pH-Triggered Carbopol®/HPMC In Situ Gel for ocular delivery of dorzolamide HCl: in vitro, in vivo, and ex vivo evaluation. AAPS PharmSciTech. 2019;20(5):210. doi:https://doi.org/10.1208/s12249-019-1431-y.
- Mahboobian MM, Seyfoddin A, Rupenthal ID, Aboofazeli R, Foroutan SM. Formulation development and evaluation of the therapeutic efficacy of brinzolamide containing nanoemulsions. Iran J Pharm Sci. 2017;16:847.
- Gohil R, Patel A, Pandya T, Dharamsi A. Optimization of brinzolamide loaded microemulsion using formulation by design approach: characterization and in-vitro evaluation. Curr Drug Ther. 2020;15(1):37–52. doi:https://doi.org/10.2174/1574885514666190104115802.
- Jiao J. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. Adv Drug Deliv Rev. 2008;60(15):1663–73. doi:https://doi.org/10.1016/j.addr.2008.09.002.
- Li X, Pan W, Ju C, Liu Z, Pan H, Zhang H, Nie S. Evaluation of Pharmasolve® corneal permeability enhancement and its irritation on rabbit eyes. DrugDeliv. 2009;16:224–29.
- Ibrahim SS. The role of surface active agents in ophthalmic drug delivery: a comprehensive review. J Pharm Sci. 2019;108(6):1923–33. doi:https://doi.org/10.1016/j.xphs.2019.01.016.
- Roggeband R, York M, Pericoi M, Braun W. Eye irritation responses in rabbit and man after single applications of equal volumes of undiluted model liquid detergent products. Food Chem Toxicol. 2000;38(8):727–34. doi:https://doi.org/10.1016/S0278-6915(00)00057-0.